1. Home
  2. RDN vs ACAD Comparison

RDN vs ACAD Comparison

Compare RDN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radian Group Inc.

RDN

Radian Group Inc.

HOLD

Current Price

$36.59

Market Cap

4.5B

Sector

Finance

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$23.39

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDN
ACAD
Founded
1977
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.8B
IPO Year
2008
2000

Fundamental Metrics

Financial Performance
Metric
RDN
ACAD
Price
$36.59
$23.39
Analyst Decision
Buy
Buy
Analyst Count
6
22
Target Price
$40.67
$30.55
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
2.73%
N/A
EPS Growth
5.61
69.12
EPS
0.89
0.02
Revenue
$1,197,084,000.00
$726,437,000.00
Revenue This Year
N/A
$18.80
Revenue Next Year
$2.66
$11.70
P/E Ratio
$40.00
$1,130.00
Revenue Growth
N/A
40.45
52 Week Low
$31.50
$19.69
52 Week High
$38.84
$28.35

Technical Indicators

Market Signals
Indicator
RDN
ACAD
Relative Strength Index (RSI) 61.97 66.87
Support Level $31.96 $20.39
Resistance Level $37.30 $27.91
Average True Range (ATR) 0.75 0.66
MACD 0.24 0.20
Stochastic Oscillator 89.97 85.08

Price Performance

Historical Comparison
RDN
ACAD

About RDN Radian Group Inc.

Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: